Regeneron Pharmaceuticals Announces That Both The FDA And EMA Have Accepted Regulatory Applications For Cemdisiran To Treat Adult Patients With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody-Positive